Physician profile
Mark Ngo
NPI 1982623468
$4,826.98
in general payments reported to CMS, 2019-2025
37 companies · $541 in 2025
The $541 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $72.95 · 2021: $1,490 · 2022: $1,018 · 2023: $965 · 2024: $495 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,150.84 | 2021-2025 | Calquence |
| Astellas Pharma US INC | $411.53 | 2019-2024 | Padcev |
| Pfizer INC. | $355.60 | 2019-2025 | |
| Celgene Corporation | $278.37 | 2021-2025 | Reblozyl |
| Amgen INC. | $213.25 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Janssen Biotech, INC. | $194.28 | 2019-2023 | Darzalex, Imbruvica, Tecvayli |
| Incyte Corporation | $193.61 | 2021-2023 | Jakafi |
| Seagen INC. | $190.63 | 2021-2023 | Padcev |
| Novartis Pharmaceuticals Corporation | $142.93 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.61 | 2021-2022 | |
| Beigene USA, INC. | $133.93 | 2023 | Brukinsa |
| Merck Sharp & Dohme LLC | $125.70 | 2019-2024 | Keytruda |
| Alexion Pharmaceuticals, INC. | $125.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $110.46 | 2019-2025 | Opdivo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $109.31 | 2021-2023 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $100.00 | 2021 | |
| Abbvie INC. | $84.20 | 2024 | |
| Boston Scientific Corporation | $78.51 | 2022 | |
| Myriad Genetic Laboratories, INC. | $66.34 | 2021-2023 | Myrisk |
| Eisai INC. | $57.55 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $53.55 | 2021 | |
| Puma Biotechnology, INC. | $47.47 | 2020-2023 | |
| Jazz Pharmaceuticals INC. | $41.46 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.47 | 2021-2023 | Ninlaro |
| Karyopharm Therapeutics INC. | $32.23 | 2022 | |
| Kite Pharma, INC. | $28.72 | 2021 | |
| Tersera Therapeutics LLC | $28.53 | 2021 | |
| Emd Serono, INC. | $27.62 | 2021 | |
| Emmaus Medical, INC. | $26.27 | 2019 | |
| Genzyme Corporation | $24.99 | 2022 | |
| Myovant Sciences INC. | $20.83 | 2021 | |
| Global Blood Therapeutics, INC. | $19.53 | 2021 | |
| Eusa Pharma (US) LLC | $18.89 | 2021 | |
| Dova Pharmaceuticals | $14.78 | 2021 | |
| Morphosys, US INC. | $12.99 | 2023 | Monjuvi |
| Array Biopharma INC | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.